In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers has now identified an enzyme that controls the activity of osteoblasts. An agent that inhibits the activity of this enzyme reduced cancer-related bone loss and the number of bone metastases in multiple myeloma and in lung and breast cancer models in mice.
Bones appear to be durable and solid. But appearances are deceptive: in fact, bone tissue is in a constant state of remodeling. Bone-degrading osteoclasts and bone-building osteoblasts ensure a fine balance in the healthy organism.
But this balance is occasionally disturbed: in osteoporosis, bone resorption takes over, so that fractures and deformities can occur. Bone metastases, which occur in the course of many cancers, are also often caused by bone resorption processes. This is also true for multiple myeloma, which originates and spreads in the bone marrow.
"Once they have penetrated the bone, many cancer cells secrete substances that suppress bone formation by osteoblasts. Patients often suffer greatly from painful bone metastases and fractures frequently occur," says the author.
So far, drugs are available that inhibit bone resorption by osteoclasts. However, the researchers believe that agents that promote bone formation by osteoblasts are also medically necessary. To identify such substances, the researchers first had to find out which signaling pathways control osteoblast activity.
In this investigation, the team identified in mouse osteoblasts the two enzymes MERTK and Typo3, so-called receptor tyrosine kinases, which regulate bone production. The function of the two enzymes was studied in mice in whose osteoblasts either one or the other receptor tyrosine kinase was genetically switched off. The result: If MERTK was inactivated, the bone mass of the animals increased. Without Typo3, on the other hand, it decreased.
This result was an indication that the activity of MERTK in osteoblasts could also contribute to the cancer-related inhibition of bone formation.
The small-molecule agent R992 inhibits MERTK activity. "R992 gave us a tool to test whether inhibiting MERTK could slow cancer-induced bone loss," says the first author of the study. When healthy mice were treated with R992, their osteoblast numbers increased and the animals' bone mass increased. Treatment with R992 also reduced bone loss and the number of bone metastases in mouse models with myeloma, lung cancer and breast cancer cell lines.
The agent R992 is not approved as a drug. To potentially study the effects of MERTK blockade in patients, the team is currently developing an antibody that specifically blocks the function of MERTK. "Bone metastases affect a great many cancer patients. Osteoporosis is also a common disease. A drug that counteracts the fatal bone loss could therefore benefit a great many sufferers. We are therefore investing in further research into the role of MERTK as a therapeutic target in pathological bone loss."
https://www.nature.com/articles/s41467-022-33938-x
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fregulation-of-bone&filter=22
Regulating bone homeostasis!
- 922 views
- Added
Edited
Latest News
Key role of a growth factor…
By newseditor
Posted 21 Jun
Bidirectional BCI functiona…
By newseditor
Posted 19 Jun
Protein aggregation clock t…
By newseditor
Posted 19 Jun
A new protein in pathologic…
By newseditor
Posted 19 Jun
How cells and tissues age?
By newseditor
Posted 19 Jun
Other Top Stories
Orphan receptor GPR158 serves as a metabotropic glycine receptor, m…
Read more
How developing nerve cells are influenced by essential amino acids
Read more
How exercise preserves physical fitness during aging
Read more
A Protein-Rich Diet Helps Mice and Flies Sleep More Soundly
Read more
Brain region linking short-term to long-term memory discovered
Read more
Protocols
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Development of an efficient…
By newseditor
Posted 12 Jun
A co-culture system of macr…
By newseditor
Posted 10 Jun
Analysis of 3D pathology sa…
By newseditor
Posted 08 Jun
Long-term expandable mouse…
By newseditor
Posted 07 Jun
Publications
Alarmin S100A8 imparts chem…
By newseditor
Posted 21 Jun
BMP7 promotes cardiomyocyte…
By newseditor
Posted 21 Jun
Relapse to cocaine seeking…
By newseditor
Posted 21 Jun
Basis of gene-specific tran…
By newseditor
Posted 21 Jun
Embryos burn fat in standby
By newseditor
Posted 20 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar